About Us

Poised to Transform the Standard of Care in Advanced Parkinson’s Disease

At Intrance Medical Systems, Inc., we are focused on rapidly advancing a next-generation therapy for advanced Parkinson's disease that has the potential to transform the standard of care and improve patient lives.

Leveraging a Proven Approach to Improve Patient Lives

Intrance is committed to bringing innovation to the advanced Parkinson's disease community. By harnessing our expertise and deep knowledge in advanced Parkinson's disease, we are acting with urgency to bring our proven therapeutic approach to the U.S. market to positively impact patient quality of life and enhance treatment outcomes. Our lead clinical product combines a proprietary pharmaceutical gel formulation of a fixed-dose combination of carbidopa, entacapone, and levodopa with a wearable, lightweight infusion pump that delivers the drug directly to the small intestine allowing for continuous use in patients with advanced Parkinson's disease. This approach is designed to overcome the clinical challenges of current treatments for advanced Parkinson's disease and is supported by clinical registration data and regulatory approvals in Europe, in addition to growing real-world patient experience in Europe. The product has been commercially launched in the Nordic countries and select European territories where it is gaining market share and user acceptance.

Next-Generation Therapy

We are focused on rapidly advancing a next-generation therapy for advanced Parkinson’s disease that has the potential to transform the standard of care and improve patient lives.

Building on the Global Success of Our Founders

 

Our approach is grounded in science and builds on the global success of our co-founders Ulf Rosén and Roger Bolsöy. As pioneers in Parkinson's disease, they have an in-depth understanding of the therapeutic area, as well as the science and real-world needs of patients and providers. Based upon substantial clinical, operational and commercial experience in the treatment of Parkinson's disease in late stages, especially device-assisted therapies that provide continuous intestinal infusion of levodopa, their work serves as the road map for our platform and technology to address serious unmet medical needs in advanced Parkinson's disease.